https://www.clinicaltrialsarena.com/news/neurorx-relief-aviptadil-data/NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.
Aviptadil is a formulation of Vasoactive Intestinal Polypeptide (VIP), which is present in high concentrations in the lungs and known to block various inflammatory cytokines. NeuroRx and Relief partnered to develop the drug in Covid-19 indication.
The drug candidate secured fast track designation from the US Food and Drug Administration (FDA) to treat respiratory distress associated with Covid-19.
